Celldex Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1983-01-01

Employees: 160

Market Cap: $2.5B

Website: http://www.celldex.com

Clinical Trials

A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Biological: CDX-0158 (formerly known as KTN-0158)

First Posted Date: 2015-12-30

Last Posted Date: 2019-06-12

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 28

Registration Number: NCT02642016

Locations: 🇺🇸
Oregon Health & Sciences University, Portland, Oregon, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 1 locations

A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer

Phase 1

Terminated

Conditions: Clear-cell Metastatic Renal Cell Carcinoma
Carcinoma, Renal Cell
Kidney Neoplasms
Urologic Neoplasms
Head and Neck Cancer
Urologic Diseases
Triple Negative Breast Cancer
Non-small Cell Lung Cancer
Urogenital Neoplasms
Neoplasms by Histologic Type

Interventions: Drug: Combination of Varlilumab and Atezolizumab

First Posted Date: 2015-09-07

Last Posted Date: 2018-04-30

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 18

Registration Number: NCT02543645

Locations: 🇺🇸
University of California - San Francisco, San Francisco, California, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 1 locations

A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients

Phase 1

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Biological: KTN3379

First Posted Date: 2015-06-17

Last Posted Date: 2019-08-01

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 12

Registration Number: NCT02473731

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379

Phase 1

Completed

Conditions: Thyroid Cancer

Interventions: Biological: KTN3379
Drug: vemurafenib

First Posted Date: 2015-05-28

Last Posted Date: 2017-09-05

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 7

Registration Number: NCT02456701

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma

Phase 1

Terminated

Conditions: Unresectable Stage III or Stage IV Melanoma

Interventions: Drug: Combination of varlilumab and ipilimumab

First Posted Date: 2015-04-10

Last Posted Date: 2017-04-07

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 9

Registration Number: NCT02413827

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

and more 5 locations

A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma

Phase 1

Terminated

Conditions: Carcinoma, Renal Cell
Neoplasms
Urogenital Neoplasms
Neoplasms by Histologic Type
Kidney Diseases
Urologic Diseases
Urologic Neoplasms
Clear-cell Metastatic Renal Cell Carcinoma
Kidney Neoplasms

Interventions: Drug: Combination of varlilumab and sunitinib

First Posted Date: 2015-03-11

Last Posted Date: 2018-07-26

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 17

Registration Number: NCT02386111

Locations: 🇺🇸
George Washington University-Medical Faculty Associates, Washington, District of Columbia, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

and more 6 locations

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Phase 1

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed
Renal Cell Carcinoma (RCC) (Phase ll Only)
Ovarian Carcinoma-Enrollment Completed
Colorectal Cancer (CRC)-Enrollment Completed

Interventions: Drug: Combination of varlilumab and nivolumab

First Posted Date: 2015-01-12

Last Posted Date: 2019-12-09

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 175

Registration Number: NCT02335918

Locations: 🇺🇸
Georgetown University, Washington, District of Columbia, United States
🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
The Stanford Center for Clinical and Translational Education and Research, Palo Alto, California, United States

and more 16 locations

A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

Phase 2

Terminated

Conditions: Melanoma

Interventions: Drug: glembatumumab vedotin
Drug: glembatumumab vedotin and varlilumab
Drug: glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)
Drug: glembatumumab vedotin and CDX-301

First Posted Date: 2014-11-27

Last Posted Date: 2019-09-06

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 132

Registration Number: NCT02302339

Locations: 🇺🇸
Florida Cancer Specialists, West Palm Beach, Florida, United States
🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 10 locations

A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs

Phase 2

Terminated

Conditions: For Donors
Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling
For Recipients
Acute Myelogenous Leukemia (AML)
Acute Lymphoblastic Leukemia (ALL)
Myelodysplastic Syndrome (MDS)
Chronic Myelogenous Leukemia (CML)
Non-Hodgkins Lymphoma (NHL)
Hodgkins Disease (HD)
Chronic Lymphocytic Leukemia (CLL)

Interventions: Drug: CDX-301
Drug: CDX-301 and plerixafor

First Posted Date: 2014-07-25

Last Posted Date: 2017-04-07

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 36

Registration Number: NCT02200380

Locations: 🇺🇸
Emory University-Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸
University of Iowa, Iowa City, Iowa, United States

and more 5 locations

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Biological: KTN3379

First Posted Date: 2013-12-18

Last Posted Date: 2017-07-24

Lead Sponsor: Celldex Therapeutics

Target Recruit Count: 64

Registration Number: NCT02014909

Locations: 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States

and more 1 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy